Maze Therapeutics (MAZE) Enterprise Value (2024 - 2026)

Maze Therapeutics has disclosed Enterprise Value across 3 years of filings, most recently posting -$352.4 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$352.4 million, down 19.71% year-over-year; the trailing twelve-month figure through Mar 2026 was -$352.4 million (down 19.71% YoY), and the FY2025 annual result was -$341.9 million, down 73.73% from the prior year.
• Enterprise Value came in at -$352.4 million for Q1 2026 at Maze Therapeutics, down from -$341.9 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$30.0 million in Q1 2024 to a low of -$383.9 million in Q3 2025.
• The 3-year median for Enterprise Value is -$264.5 million (2025), against an average of -$243.2 million.
• Across the five-year window, Enterprise Value slumped 880.49% in 2025 and retreated 19.71% in 2026, its largest moves.
• Maze Therapeutics' Enterprise Value stood at -$196.8 million in 2024, then plunged by 73.73% to -$341.9 million in 2025, then declined by 3.06% to -$352.4 million in 2026.
• The last three Enterprise Value figures came in at -$352.4 million (Q1 2026), -$341.9 million (Q4 2025), and -$383.9 million (Q3 2025), per Business Quant data.